MBX Biosciences (MBX) Competitors $7.38 -0.05 (-0.67%) Closing price 04/15/2025 04:00 PM EasternExtended Trading$7.38 0.00 (-0.07%) As of 04/15/2025 04:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock MBX vs. SNDX, BGM, WVE, MLYS, ETNB, COLL, DYN, ELVN, RCUS, and CMRXShould you be buying MBX Biosciences stock or one of its competitors? The main competitors of MBX Biosciences include Syndax Pharmaceuticals (SNDX), Qilian International Holding Group (BGM), Wave Life Sciences (WVE), Mineralys Therapeutics (MLYS), 89bio (ETNB), Collegium Pharmaceutical (COLL), Dyne Therapeutics (DYN), Enliven Therapeutics (ELVN), Arcus Biosciences (RCUS), and Chimerix (CMRX). These companies are all part of the "pharmaceutical products" industry. MBX Biosciences vs. Syndax Pharmaceuticals Qilian International Holding Group Wave Life Sciences Mineralys Therapeutics 89bio Collegium Pharmaceutical Dyne Therapeutics Enliven Therapeutics Arcus Biosciences Chimerix MBX Biosciences (NYSE:MBX) and Syndax Pharmaceuticals (NASDAQ:SNDX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, risk, valuation, media sentiment, analyst recommendations, community ranking, institutional ownership and dividends. Is MBX or SNDX more profitable? MBX Biosciences' return on equity of 0.00% beat Syndax Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets MBX BiosciencesN/A N/A N/A Syndax Pharmaceuticals N/A -64.34%-57.72% Does the media refer more to MBX or SNDX? In the previous week, MBX Biosciences had 3 more articles in the media than Syndax Pharmaceuticals. MarketBeat recorded 10 mentions for MBX Biosciences and 7 mentions for Syndax Pharmaceuticals. Syndax Pharmaceuticals' average media sentiment score of 0.65 beat MBX Biosciences' score of 0.64 indicating that Syndax Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MBX Biosciences 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Syndax Pharmaceuticals 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Which has better valuation & earnings, MBX or SNDX? MBX Biosciences has higher earnings, but lower revenue than Syndax Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMBX BiosciencesN/AN/AN/AN/AN/ASyndax Pharmaceuticals$23.68M41.17-$209.36M-$3.73-3.04 Does the MarketBeat Community favor MBX or SNDX? Syndax Pharmaceuticals received 384 more outperform votes than MBX Biosciences when rated by MarketBeat users. However, 100.00% of users gave MBX Biosciences an outperform vote while only 65.38% of users gave Syndax Pharmaceuticals an outperform vote. CompanyUnderperformOutperformMBX BiosciencesOutperform Votes7100.00% Underperform VotesNo VotesSyndax PharmaceuticalsOutperform Votes39165.38% Underperform Votes20734.62% Do analysts recommend MBX or SNDX? MBX Biosciences presently has a consensus price target of $37.50, indicating a potential upside of 408.13%. Syndax Pharmaceuticals has a consensus price target of $36.20, indicating a potential upside of 219.51%. Given MBX Biosciences' stronger consensus rating and higher probable upside, equities research analysts clearly believe MBX Biosciences is more favorable than Syndax Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MBX Biosciences 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00Syndax Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.90 SummaryMBX Biosciences beats Syndax Pharmaceuticals on 6 of the 10 factors compared between the two stocks. Remove Ads Get MBX Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for MBX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MBX vs. The Competition Export to ExcelMetricMBX BiosciencesPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$246.67M$6.33B$5.33B$18.52BDividend YieldN/A3.24%5.11%4.22%P/E RatioN/A6.7921.7331.15Price / SalesN/A225.96379.2025.69Price / CashN/A65.6738.1517.53Price / BookN/A5.866.464.29Net IncomeN/A$141.86M$3.20B$1.02B7 Day Performance15.31%4.50%2.86%-0.79%1 Month Performance-15.17%-12.65%-8.55%-6.88%1 Year PerformanceN/A-11.06%10.47%1.74% MBX Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MBXMBX Biosciences2.1485 of 5 stars$7.38-0.7%$37.50+408.1%N/A$246.67MN/A0.0036Gap DownSNDXSyndax Pharmaceuticals3.3478 of 5 stars$11.24+0.7%$36.20+222.1%-47.6%$967.14M$23.68M-3.10110Gap DownBGMQilian International Holding GroupN/A$9.65-3.6%N/AN/A$938.19M$25.10M0.00298Positive NewsWVEWave Life Sciences4.1709 of 5 stars$6.00+6.2%$22.18+269.7%+9.4%$920.92M$108.30M-5.41240Short Interest ↑Analyst RevisionMLYSMineralys Therapeutics2.3958 of 5 stars$13.92+3.9%$33.00+137.1%+12.5%$873.97MN/A-3.8228Insider TradeShort Interest ↑Gap UpETNB89bio2.5885 of 5 stars$5.92+7.1%$27.56+365.5%-36.2%$864.23MN/A-2.0340Short Interest ↑COLLCollegium Pharmaceutical4.0797 of 5 stars$26.73+1.6%$43.60+63.1%-22.8%$858.89M$631.45M11.52210Positive NewsGap DownDYNDyne Therapeutics3.5747 of 5 stars$7.47+6.1%$47.46+535.4%-69.1%$845.01MN/A-2.10100ELVNEnliven Therapeutics2.5632 of 5 stars$17.19+4.1%$40.33+134.6%-14.5%$842.38MN/A-9.0550RCUSArcus Biosciences2.4498 of 5 stars$7.67-6.2%$30.25+294.4%-50.9%$806.41M$258M-2.43500CMRXChimerix2.9082 of 5 stars$8.54+0.2%$8.53-0.1%+834.8%$801.09M$212,000.00-9.0990 Remove Ads Related Companies and Tools Related Companies Syndax Pharmaceuticals Competitors Qilian International Holding Group Competitors Wave Life Sciences Competitors Mineralys Therapeutics Competitors 89bio Competitors Collegium Pharmaceutical Competitors Dyne Therapeutics Competitors Enliven Therapeutics Competitors Arcus Biosciences Competitors Chimerix Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:MBX) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersThe Crypto Market is About to Change LivesI've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | SponsoredTwo Unmistakable Patterns Return…The signs suggest we're entering one of those rare periods now. That's why Central Banks are buying gold at...Golden Portfolio | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredIs it CRAZY to still want reliable profits, despite this market?Larry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredFirst look: The $3,500 iPhoneDid you hear that just before Trump's tariffs took effect, Apple sent five cargo planes packed with MacBooks a...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MBX Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MBX Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
